Circadian rhythm sleep disorder, jet lag type

Summary

Circadian rhythm sleep disorder, jet lag type (MONDO:0024381) is a disease and 6 clinical trials. Top therapeutic interventions include hydrocortisone and tasimelteon. A subtype of circadian rhythm sleep disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	circadian rhythm sleep disorder, jet lag type
Mondo ID	MONDO:0024381
ICD-10-CM	G47.25
UMLS	C0231311
MedGen	115901
Is cancer (heuristic)	no

Also known as: jet lag

Disease family

This is a subtype of circadian rhythm sleep disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › sleep disorder › sleep-wake disorder › circadian rhythm sleep disorder › circadian rhythm sleep disorder, jet lag type

Related subtypes (7): advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, rapid eye movement sleep disorder, circadian rhythm sleep disorder, delayed sleep phase type, circadian rhythm sleep disorder, advanced sleep phase type, circadian rhythm sleep disorder, irregular sleep wake type, circadian rhythm sleep disorder, shift work type

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03373201	PHASE3	COMPLETED	Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
NCT00097474	PHASE2	COMPLETED	Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag
NCT00950885	Not specified	COMPLETED	Melatonin Treatment for Induced Transient Insomnia
NCT05382923	Not specified	UNKNOWN	Facilitating Adjustment to Simulated Jet Lag
NCT05618405	Not specified	COMPLETED	Changes in Circadian Rhythm After Anaesthesia in Children
NCT05700136	Not specified	UNKNOWN	Factors Associated With Infant Circadian Rhythm, Growth, and Temperament

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HYDROCORTISONE	4	1
TASIMELTEON	4	1